|
1
|
Smith LE: Pathogenesis of retinopathy of
prematurity. Growth Horm IGF Res. 14(Suppl A): S140–S144. 2004.
View Article : Google Scholar
|
|
2
|
Hartnett ME and Penn JS: Mechanisms and
management of retinopathy of prematurity. N Engl J Med.
368:1162–1163. 2013.PubMed/NCBI
|
|
3
|
Shrestha JB, Bajimaya S, Sharma A,
Shresthal J and Karmacharya P: Incidence of retinopathy of
prematurity in a neonatal intensive care unit in Nepal. J Pediatr
Ophthalmol Strabismus. 47:297–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Romagnoli C, Tesfagabir MG, Giannantonio C
and Papacci P: Erythropoietin and retinopathy of prematurity. Early
Hum Dev. 87(Suppl 1): S39–S42. 2011. View Article : Google Scholar
|
|
5
|
Suk KK, Dunbar JA, Liu A, et al: Human
recombinant erythropoietin and the incidence of retinopathy of
prematurity: a multiple regression model. J AAPOS. 12:233–238.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Figueras-Aloy J, Alvarez-Domínguez E,
Morales-Ballus M, Salvia-Roiges MD and Moretones-Suñol G: Early
administration of erythropoietin in the extreme premature, a risk
factor for retinopathy of prematurity? An Pediatr (Barc).
73:327–333. 2010.(In Spanish).
|
|
7
|
Shannon K: Recombinant human
erythropoietin in neonatal anemia. Clin Perinatol. 22:627–640.
1995.PubMed/NCBI
|
|
8
|
Xiong SQ, Xia XB, Xu HZ and Jiang J:
Suppression of retinal neovascularization by small-interference RNA
targeting erythropoietin. Ophthalmologica. 223:306–312. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heeschen C, Aicher A, Lehmann R, et al:
Erythropoietin is a potent physiologic stimulus for endothelial
progenitor cell mobilization. Blood. 102:1340–1346. 2003.
View Article : Google Scholar
|
|
10
|
Zuppa AA, Alighieri G, Fracchiolla A, et
al: Comparison between two treatment protocols with recombinant
human erythropoietin (rHuEpo) in the treatment of late anemia in
neonates with Rh-isoimmunization. Pediatr Med Chir. 34:186–191.
2012. View Article : Google Scholar
|
|
11
|
Thomaidis T, Weinmann A, Sprinzl M, et al:
Upper-GI-Group of AIO (Arbeitsgemeinschaft Internistische
Onkologie), Germany: Erythropoietin treatment in
chemotherapy-induced anemia in previously untreated advanced
esophagogastric cancer patients. Int J Clin Oncol. 19:288–296.
2013. View Article : Google Scholar
|
|
12
|
Fenner MH and Ganser A: Erythropoietin in
cancer-related anemia. Curr Opin Oncol. 20:685–689. 2008.
View Article : Google Scholar
|
|
13
|
Shah N, Jadav P, Jean-Baptiste D, et al:
The effect of recombinant human erythropoietin on the development
of retinopathy of prematurity. Am J Perinatol. 27:67–71. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brown MS, Barón AE, France EK and Hamman
RF: Association between higher cumulative doses of recombinant
erythropoietin and risk for retinopathy of prematurity. J AAPOS.
10:143–149. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Patz A: Current concepts of the effect of
oxygen on the developing retina. Curr Eye Res. 3:159–163. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smith LE, Wesolowski E, McLellan A, et al:
Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci.
35:101–111. 1994.PubMed/NCBI
|
|
17
|
Neufeld G, Cohen T, Gengrinovitch S and
Poltorak Z: Vascular endothelial growth factor (VEGF) and its
receptors. FASEB J. 13:9–22. 1999.PubMed/NCBI
|
|
18
|
Sato T, Kusaka S, Shimojo H and Fujikado
T: Vitreous levels of erythropoietin and vascular endothelial
growth factor in eyes with retinopathy of prematurity.
Ophthalmology. 116:1599–1603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McVicar CM, Colhoun LM, Abrahams JL, et
al: Differential modulation of angiogenesis by
erythropoiesis-stimulating agents in a mouse model of ischaemic
retinopathy. PLoS One. 5:e118702010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cooke JP and Losordo DW: Nitric oxide and
angiogenesis. Circulation. 105:2133–2135. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rezaeian F, Wettstein R, Egger JF, et al:
Erythropoietin-induced upregulation of endothelial nitric oxide
synthase but not vascular endothelial growth factor prevents
musculocutaneous tissue from ischemic damage. Lab Invest. 90:40–51.
2010. View Article : Google Scholar
|
